Published Thu, 09 Jul 2020 10:09:44 -0400 on Seeking Alpha
Seeking AlphaDividend Ideas | Healthcare Merck: Amazing Oncology Division, Underwhelming Dividend OpportunityJul. 9, 2020 10:09 AM ET|| About: Merck & Co., Inc. (MRK), Includes: ABBV, JNJ, PFEby: The Dividend PortfolioThe Dividend Portfolio Dividend investing, dividend growth investing, value, long-term horizonSummaryMerck, an international pharmaceutical company, has experienced strong growth of key financial metrics over the last few years driven by the success of some of their key blockbuster including Keytruda.
This has resulted in a strong growth of Merck's oncology division over the last few years, which has significantly outperformed competitors during the same time period.
However, most of Merck's other pharmaceutical divisions have experienced broad declines over the last few years, and the company faces potential challenges from their dependence on Keytruda.
Furthermore, recent challenges covering the dividend with free cash flow and the dividend growth opportunities of other pharmaceutical companies don't necessarily make Merck's dividend very appealing.
Taken together, I believe that Merck is fairly valued and has the potential to grow, though I believe that there are better dividend growth opportunities in the pharmaceutical industry.
Merck (MRK) is a major international pharmaceutical company with a history of experiencing extended growth and decline phases. From the early 2000s to the mid-2010, Merck faced challenges from settlements, divestitures, and the loss of their exclusivity of key patents. Recently, the success of some of Merck's blockbuster therapeutics, especially Keytruda, has resulted in strong growth of key financial metrics over the last few years. This has led to significant sale increases for Merck's oncology and vaccine divisions over the last five years, with more opportunities for these divisions to expand moving forward. However, Merck faces challenges growing its other pharmaceutical divisions and needs to... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|JOHNSON & JOHNSON||130.43||21.6||6.03||3.80||2.93|
Older articles featuring Abbvie (ABBV):Dividend Challenger Highlights: Week Of August 9
DTD Has A Portfolio Of Quality Dividend Stocks That Should Be Able To Weather The Challenge Caused By COVID-19
3 Low-Beta Blue Chips With High Dividend Yields
The Retiree's Dividend Portfolio - Jane's June Update: Record Dividends During COVID-19
The 14 Best High-Yield Dividend Aristocrats Retirees Can Safely Buy Right Now
Dividend Aristocrats Flaunt 7 Surefire August Selections
In Search Of The Best High-Yield Opportunities In The Market Today
June Portfolio Dividend Update
The 33 Fit Dividend Stocks For Our Times: July's, 2020 Assortment
Dividend Challenger Highlights: Week Of July 12